Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Ascletis submits Chinese NDA for second HCV therapy

July 31, 2018 9:23 PM UTC

Ahead of its Hong Kong trading debut Wednesday, Ascletis Pharma Inc. (HKSE:1672) said Tuesday it submitted an NDA to China's State Drug Administration for HCV therapy ravidasvir. The second-generation HCV NS5A protein inhibitor received expedited review from the agency in 2016.

In June, Ascletis launched HCV drug Ganovo danoprevir in China. Ascletis has rights to the HCV NS3/4A protease inhibitor from Roche (SIX:ROG; OTCQX:RHHBY) in China, Hong Kong, Macau and Taiwan...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Ascletis Pharma Inc.

BCIQ Target Profiles

HCV NS5A protein